anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To obtain a powdery fat oil-albumin complex insoluble in water, free from hygroscopicity and having excellent storage stability, by bonding a liquid fat oil with albumin. CONSTITUTION:Albumen, serum albumin, etc., are dissolved in water. A part of the water may be replaced with a water-soluble solvent such as ethanol, glycerol, etc., in the above dissolution process. There is not restriction in the concentration of the albumin aqueous solution. The liquid fat oil is an oil which is liquid at normal temperature, fat or fatty acid which becomes liquid when heated or dissolved in a solvent or an animal or vegetable containing the above oil. The fat oil is added to the prepared albumin aqueous solution and stirred at high speed. The components are almost completely reacted with each other irrespective of the ratio of the components and a precipitate corresponding to the ratio is produced. The fat oil may be incorporated with vitamin E, etc., as an antioxidant. The precipitate is dried by conventional method to remove the solvent and obtain the objective product.
Pramipexole displays linear pharmacokinetics over the clinical dosage range. Its terminal half-life is about 8 hours in young healthy volunteers and about 12 hours in elderly volunteers (see CLINICAL PHARMACOLOGY,Pharmacokinetics in Special Populations). Steady-state concentrations are achieved within 2 days of dosing.

### Absorption

Pramipexole is rapidly absorbed, reaching peak concentrations in approximately 2 hours. The absolute bioavailability of pramipexole is greater than 90%, indicating that it is well absorbed and undergoes little presystemic metabolism. Food does not affect the extent of pramipexole absorption, although the time of maximum plasma concentration (Tmax) is increased by about 1 hour when the drug is taken with a meal.

### Distribution

Pramipexole is extensively distributed, having a volume of distribution of about 500 L (coefficient of variation [CV]=20%). It is about 15% bound to plasma proteins. Pramipexole distributes into red blood cells as indicated by an erythrocyte to plasma ratio of approximately two.

### Metabolism and Elimination

The terminal half-life of pramipexole is about 8 hours in healthy volunteers and 12 hours in elderly volunteers. 

Urinary excretion is the major route of pramipexole elimination, with 90% of a pramipexole dose recovered in urine, almost all as unchanged drug. Nonrenal routes may contribute to a small extent to pramipexole elimination, although no metabolites have been identified in plasma or urine. The renal clearance of pramipexole is approximately 400 mL/min (CV=25%), approximately three times higher than the glomerular filtration rate. Thus, pramipexole is secreted by the renal tubules, probably by the organic cation transport system.
It is the investigators expectation that this combination will induce apoptotic pathways downstream of biochemical mechanisms of resistance and synergistically induce pathways for apoptosis that are non-p53 dependent, which have not been previously explored in chemotherapy trials for this cancer. ABRAXANE® is novel in that it induces apoptosis to the same degree in mutant and wt p53 cancers. Mutant p53 tumors occur in 80-90% of PC and mutant p53 is thought of as one of the major mechanisms of drug resistance.

Furthermore, the investigators will be starting Xeloda and gemcitabine at slightly lower doses than the initial GTX studies. This is because the investigators have found that the efficacy is maintained at these slightly lower doses while side effects are minimized. The reason that GTX works at lower doses, as well as higher doses, is the synergy between drugs. Drug regimens that are synergistic can maintain their antitumor effect at doses lower than in non-synergistic regimens, but must maintain their dose intensity to achieve their anti-tumor effect. RECIST 1.1 criteria will be utilized for judging response, progression and stable disease. Overall assessment of the data will be by intention to treat analysis (ITT).
Sugarcane smut is the most damaging disease that is present almost across the globe, causing mild to severe yield losses depending upon the cultivar types, pathogen races and climatic conditions. Cultivation of smut-resistant cultivars is the most feasible and economical option to mitigate its damages. Previous investigations revealed that there is a scarcity of information on early detection and effective strategies to suppress etiological agents of smut disease due to the characteristics overlapping within species complexes. In this study, 104 sugarcane cultivars were screened by artificial inoculation with homogenate of all possible pathogen races of Sporisorium scitamineum during two consecutive growing seasons. The logistic smut growth pattern and the disease intrinsic rate were recorded by disease growth curve. Variable levels of disease incidence i.e., ranging from 0 to 54.10% were observed among these sugarcane cultivars. Besides, pathogen DNA in plant shoots of all the cultivars was successfully amplified by PCR method using smut-specific primers except 26 cultivars which showed an immune reaction in the field trial. Furthermore, the plant germination and tillering of susceptible sugarcane cultivars were greatly influenced by pathogen inoculation. In susceptible cultivars, S. scitamineum caused a significant reduction in setts germination, coupled with profuse tillering, resulting in fewer millable canes. Correlation analysis demonstrated that there was a positive relationship between reduction in setts germination and increase in the number of tillers. The present study would be helpful for the evaluation of smut resistance in a wide range of sugarcane germplasm, especially from the aspects of setts germination and tillers formation, and it also screened out several excellent germplasm for potential application in sugarcane breeding.
A finisher composition in the form of an oil-in-water emulsion. The continuous aqueous phase of the emulsion is from about 20 to 85 wt% of water. The dispersed oil phase of the emulsion includes a non-volatile oil, which is at least 50 % by weight of a liquid UV agent. The composition also includes from about 10 to 25 wt% of substantially spherical starch particles, silicone elastomer particles, or a combination of these. The particles have a particle size of from about 2 to 40 microns. The weight ratio of the non-volatile oil to the particles is from about 1:10 to about 1:1. The composition is substantially free of glycerin and, optionally, includes from about 1 to 20 wt% of a volatile oil.
The present invention relates to a Chinese traditional patent medicine for treating diabetic stroke, which takes more than 10 Chinese herbal medicines of nacre, dendrobium, desert-living cistanche, Chinese magnoliavine fruit etc. as the raw materials. The present invention has the effects of nourishing liver and kidney, tranquilizing and inducing resuscitation. Based on the differential treatment of the traditional Chinese medicine, the invention is developed by combining the latest scientific research results with the traditional Chinese medicine. The present invention aims at providing the Chinese traditional patent medicine for treating diabetic stroke. The present invention is characterized by accurate efficacy, safety, convenience, no toxicity or side effects and low price.
PCT No. PCT/FR92/01123 Sec. 371 Date Aug. 29, 1994 Sec. 102(e) Date Aug. 29, 1994 PCT Filed Feb. 12, 1992 PCT Pub. No. WO93/11232 PCT Pub. Date Jun. 10, 1993A cytokine that is a specific antagonist of induction by interferon-gamma of the expression of class II histocompatibility antigens at the cell surface is disclosed. The cytokine is naturally secreted by cells or is the expression product of an exogenous DNA sequence in prokaryotic or eukaryotic cells. Also disclosed is a DNA sequence that codes, on expression in a host cell, for a cytokine having a biological activity that is a specific antagonist of induction by interferon-gamma of the expression of class II histocompatibility antigens at the cell surface. A method for preparing the cytokine is further disclosed. Finally, a therapeutic composition containing the cytokine is disclosed.
Pediatric procedural sedation (PPS), formerly known as conscious sedation, is often used outside the operating room for various procedures. Twenty years ago, nearly all cases of PPS were performed by pediatric intensivists, dentists, emergency medicine physicians, and anesthesiologists, due to the urgent nature of procedures in their settings. However, with the emergence of pediatric hospital medicine as a board-certified subspecialty, many children's hospitals have created dedicated PPS teams. These teams, composed of highly trained physicians and ancillary staff, are well-suited for procedures, quality measures, and multidisciplinary care. The wider availability of sedation outside the operating room allows other pediatric subspecialties, such as surgery and oncology, to use PPS in ensuring safe and timely interventions for their patients. This article will cover PPS as an alternative to anesthesia for otherwise healthy children and aim to answer frequent questions that arise regarding medications, risks, and candidacy for PPS. [Pediatr Ann. 2024;53(9):e324-e329.].
PROBLEM TO BE SOLVED: To obtain a hair tonic capable of improving the function of the hair of the head and scalp, preventing the alopecia and having hair tonic and growth effects. SOLUTION: This hair tonic contains extracted solutions obtained by immersing Sesamum indicum L., Swertia japonica Makino and Hibiscus syriacus L. in an alcoholic extracted solution of Impatiens balsamica L. as a solvent as active ingredients. The amounts of the ingredients are 2-4 pts.wt. extract solution of the Impatiens balsamica L., 2-4 pts.wt. aqueous solution containing ethyl alcohol at >=20 deg., 3-5pts. wt. extract solution of the Sesamum indicum L., 1-2 pts.wt. extracted solution of the Swertia japonica Makino, 1-2 pts.wt. extracted solution of the Hibiscus syriacus L, and, as necessary, further 1-2 pts.wt. extracted solution of a seaweed is mixed therewith. The resultant mixture is then allowed to stand for 7-10 days and aged.  Furthermore, a coloring matter, a perfume, a germicide, a preservative, etc., are suitably blended and prepared as a hair tonic, a hair lotion, a hair conditioner, a shampoo, a rinse, etc., for use.
Breast microcalcifications are currently classified using the BI-RADS radiological scale. In case of suspicious microcalcifications (B3), it is recommended to perform a biopsy assessment for histopathological evaluation. However, about 70-80% of performed biopsies shows benign histology that does not require surgical treatment. Core biopsies are invasive procedures with a biological, psychological (patient discomfort), organizational and economic (for the Health Care System) costs. Therefore, accuracy's improvement in radiological classification of microcalcifications is essential. Recently, various approaches have been reported in the literature to detect and classify microcalcification as benign or suspicious in digital mammograms. Analysis methods based on the use of deep learning (DL) have also emerged as promising for processing mammography images. Convolutional neural networks (CNNs) are currently the state of the art for image classification in many application fields in the field of computer vision. This study intends to implement a classification method for breast microcalcifications (as benign or malign) with Artificial Intelligence (AI) techniques on mammographic images, evaluating the diagnostic performance (accuracy) of this approach. The evaluation will be conducted with reference to the standard radiological approach (BI-RADS classification).

Together with the application of AI systems to mammographic imaging, a further current clinical need is the development of a diagnostic tool able to determining in-situ the biomolecular characteristics of microcalcifications, accurately discriminating their nature without take tissue, fixation and embedding of the sample in paraffin, and without highly specialized evaluation by the pathologist. Raman spectroscopy (RS) is a highly specific method from the biomolecular point of view and, at the same time, it is compatible with in-vivo measurements. It consists in a biophotonic approach able to explore molecular composition of a given sample through its direct irradiation (through laser light) and the simultaneous acquisition of emission signals. RS information could be combined togheter with imaging features to implement an AI model for the combined classification of breast microcalcifications
Type 2 diabetes (T2D) is the leading cause of chronic kidney disease (CKD). In addition, the cardiovascular prevalence in diabetic patients is around 32.2%, with a two-fold increased mortality risk compared to those without diabetes. Recent investigations have shed light on the promising cardioprotective and nephroprotective benefits of sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1RA), and nonsteroidal mineralocorticoid receptor antagonists (nsMRAs) for individuals with T2D. The evidence robustly indicates that SGLT2i and GLP-1RA significantly reduce the risk of CKD and cardiovascular disease (CVD), all while effectively managing blood glucose levels. Furthermore, combining SGLT2i with nsMRAs amplifies the benefits, potentially offering a more profound reduction in cardiovascular and renal outcomes. The data analysis strongly supports the integration of these pharmacological agents in the management strategies for CKD and CVD prevention among T2D patients, highlighting the importance of awareness among nephrologists, especially in regions with limited healthcare resources.
This will be a double-blind, placebo-controlled study with 4 parallel treatment groups. Subjects will be screened for up to 28 days before study drug administration to ensure that all eligibility criteria are met. On Day 1, subjects will be randomized to 1 of 4 dose groups of 15 subjects each (INCB047986 4 mg, 8 mg, 12 mg, or placebo QD). Study drug will be self administered on Days 1 through 28. A follow-up telephone call to the subject to assess safety will occur at Day 42. A final safety and efficacy evaluation will be performed at the Day 58 visit.
Golimumab is a type of tumor necrosis factor (TNF) inhibitor. TNF is a naturally occurring substance in the body and this substance may cause long-term inflammation. Golimumab may help treat this disease by blocking the activity of TNF in the body and reducing the symptoms of severe, persistent asthma.This study will assess the safety and effectiveness of subcutaneously (under the skin) administered golimumab and determine if there is a reduction of signs and symptoms in patients with active severe, persistent asthma. The effect of subcutaneously (SC) administered golimumab on the quality of life in patients with severe, persistent asthma will also be assessed. About 200 patients will take part in the study at approximately 60 centers worldwide. Participation in the study will last for about 42 weeks. The study consists of 3 phases: the screening phase (lasting between 1 and 4 weeks), the treatment phase (20 weeks), and the follow-up phase (20 weeks). Visits are scheduled to occur once every 4 weeks during the treatment and follow-up phases of the study. Patients eligible to take part in this study will be randomly placed into one of the following study groups: Group 1: Placebo (an inactive or dummy treatment that looks the same as the study drug, golimumab, but does not contain any active medication) from Week 0 through Week 20. Group 2: Golimumab 100 mg from Week 0 through Week 20. This study is "blinded." This means that neither patient nor study doctor will know in which group a patient is placed. However, if needed for safety or health reasons, the study doctor can find out a patient's study group at any time.

Patients will receive an injection (under the skin) of placebo (Group 1) or golimumab 100 mg (Group 2) every 4 weeks from Week 0 through Week 20.
A computer-based system for monitoring product usage, value, and suitability for use or sale. The system can include one or more processors configured to process and manage data. Additionally, the system can also include product packaging comprising a machine-readable medium. Notably, the machine-readable medium can comprise product information among other types of information. The one or more processors can be configured for receiving the product information of the machine-readable medium. The machine-readable medium and corresponding medication information can be adjusted based on automated signals or interactive signals, where the signals are generated based on current or historical data regarding the product or the packaging.
Signs of overdose may include confusion, drowsiness, continuing headache, problems with passing urine and rapid weight gain due to fluid retention. (See WARNINGS.) In case of overdosage, the dosage should be reduced, frequency of administration decreased, or the drug withdrawn according to the severity of the condition. 

There is no known specific antidote for desmopressin acetate or Desmopressin Acetate Injection 4 mcg/mL. 

An oral LD 50 has not been established. An intravenous dose of 2 mg/kg in mice demonstrated no effect.
The invention relates to a set of siRNA molecules used for effectively down-regulating Mortalin/HSPA9/Grp75 expressions. The target points of the siRNA molecules are positioned at coding regions of Mortalin/HSPA9/Grp75mRNA. With the siRNA molecules, Mortalin/HSPA9/Grp75 expressions can be effectively down-regulated. When Mortalin/HSPA9/Grp75 expressions are down-regulated by using the siRNA molecules, sensitivity of drug-resistant ovarian cancer cells to chemotherapeutics is improved, and invasiveness of the drug-resistant ovarian cancer cells to chemotherapeutics is reduced. With the siRNA molecules, drug-resistance of ovarian cancer cells can be inverted, invasiveness of ovarian cancer cells can be reduced, and ovarian cancer treatment effect can be improved. The invention also provides a carrier containing the siRNA molecules, an application of the siRNA molecules, and a composition of the siRNA molecules and chemotherapeutics.
Piriformis syndrome is a misdiagnosed cause of sciatica leg or buttock pain and disability. The male and female incidence ratio of PS is 6.1. The fascial distortion model is a targeted manual technique and decodes categorized manual gestures (pain-related body language) to 6 pathophysiological mechanisms involved in the etiology of pain. Integrated neuromuscular inhibition technique(INIT) is a combination of muscle energy technique(MET) and positional release technique(PRT).

All previous studies in which integrated neuromuscular inhibition technique(INIT) and fascial distortion model(FDM) has been performed on different muscles of the body has shown greater improvement as compared to other techniques. Comparative effects of fascial distortion model with integrated neuromuscular inhibition technique and fascial distortion model on Piriformis Syndrome has not been addressed yet. There is very limited data available on this protocol. Therefore, this study aims to compare the effects of facial distortion model with and without integrated neuromuscular inhibition technique.
The present invention relates to a method of using 17alpha-dihydroequilenin and metabolic conjugates thereof to prevent and reduce atherogenesis in males and females without causing endometrial proliferation in females and without producing feminizing changes in males. 17alpha-dihydroequilenin was evaluated for its effects on plasma lipid and lipoprotein, glucose, insulin concentrations, coronary artery vasomotor function, and reproductive organ and mammary gland proliferation in atherosclerotic mammals. 17alpha-dihydroequilenin was found to prevent endothelium-dependent vasoconstriction in males (p<0.05) and ovariectomized females (p<0.08). 17alpha-dihydroequilenin treatment increased plasma apolipoprotein A-1 concentrations (p<0.05) and lowered fasting insulin concentrations (p<0.05) without changing fasting plasma glucose concentrations in males. 17alpha-dihydroequilenin had no other effects on plasma lipid and lipoprotein concentrations in either males or females. Also, 17alpha-dihydroequilenin exhibited no trophic effects on the uterus, endometrium, or breast, and no effect on either prostatic or testicular weight. Thus, 17alpha-dihydroequilenin may prevent breast and prostatic hyperplasia and neoplasia, and has no feminizing effects on the male urogenital system or mammary gland.
The invention discloses a copolymer of a fibroin and a poly L-lactic acid. The copolymer comprises the following structure, the molecular weight of the copolymer is between 5,000 and 180,000, and the mass ratio of the fibroin component to the poly L-lactic acid component is between 0.5/99.5 and 99.5/0.5. The invention also discloses a melt polymerization preparation method for the copolymer and application of the copolymer in biomedical materials. The melt polymerization preparation method for the copolymer comprises the following steps: perform ring-opening polymerization on L-lactide in a melt state; copolymerizing the L-lactide with the fibroin; and preparing the copolymer of the fibroin and the poly L-lactic acid, wherein the fibroin serving as a hydrophilic radical is introduced into the poly L-lactic acid. A solvent is not used in the polymerization technology, so the technology is simple and the product cost is low. The method can prepare copolymers of the fibroin and the poly L-lactic acid with different number-average molecular weights. The prepared copolymer of the fibroin and the poly L-lactic acid can improve the hydrophilcity, the biocompatibility and cellular affinity of a poly lactic acid material and control the degradation speed of the material.
Patients randomised to intervention group will continue home exercise training that will last 12 weeks and consists of endurance, flexibility, balance and cardiovascular resistance training performed with low to moderate intensity, in 20-60 minutes sessions, five times a week. Study participants will be asked to wear wrist and chest unobtrusive devices during active day time or at least during the training session and two hours before and after. Study participants well receive telephone calls every other week and were asked to answer questions regarding their health and physical activity.